Moderna, Merck Say mRNA Melanoma Vaccine Succeeded in Phase 3
Moderna and Merck say their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial — a first for the mRNA platform in cancer.
Topic
Mrna Vaccine
Topic
Mrna Vaccine
Moderna and Merck Report Melanoma Vaccine Success in Large Trial
Moderna and Merck report their personalized mRNA melanoma vaccine succeeded in a large clinical trial, a milestone for mRNA cance…
Moderna-Merck mRNA Vaccine Succeeds in Late-Stage Melanoma Trial
Moderna and Merck said their mRNA cancer vaccine succeeded in a late-stage melanoma trial, per statnews.com, but effect size, end…
Personalised mRNA Vaccine Stops Melanoma Returning in Reported Breakthrough
A personalised mRNA cancer vaccine stopped melanoma from returning, Gavi reports, marking a milestone for individualised neoantig…
Inside an mRNA Melanoma Vaccine Trial: A Patient's View
After cheek melanoma excision in 2023, tennis coach Mark Orwig, 73, joined a global mRNA cancer vaccine trial scientists say coul…
Moderna–Merck Melanoma Combo Cuts Spread Risk at Five Years
Moderna and Merck report their mRNA cancer vaccine–pembrolizumab combination cut the risk of melanoma spread at five years, a dur…
Moderna Shares Surge 29.1% on Melanoma Vaccine Data
Moderna stock jumped 29.1% after reported melanoma vaccine success and Middle East expansion talks, boosting market confidence in…
Moderna Shares Jump on Melanoma Vaccine Trial Readout
Moderna shares surged after a melanoma vaccine trial delivered what observers called a landmark moment, moving markets and signal…
mRNA Cancer Vaccine Plus Keytruda Boosts Melanoma Survival
An mRNA cancer vaccine combined with Keytruda sharply improved survival in melanoma patients, UCHealth trial results show, advanc…
Personalized mRNA Cancer Vaccine Emerges in Melanoma Fight
Individually manufactured mRNA cancer vaccines are entering the melanoma fight, bringing the pandemic-era platform into dermatolo…